Neuropathic Pain
📧 Sign up to get email alerts when something new happens for Neuropathic Pain.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS withdrawal · 2026-03-27Clinical Trial Update: Electroencephalographic (EEG) Profils for Patients on Intravenous Ketamine.
A clinical trial assessing electroencephalographic profiles in neuropathic pain patients treated with intravenous ketamine has been withdraw…
-
CLINICAL_TRIALS withdrawal · 2025-09-09Clinical Trial Update: Photobiomodulation on Neuropathic Pain and Sensation Post-mastectomy [NA]
A Tufts University clinical trial evaluating photobiomodulation for neuropathic pain and sensation changes after mastectomy has been withdra…
-
CLINICAL_TRIALS withdrawal · 2025-06-03Clinical Trial Update: Surgical Treatments for Neuroma Pain in Amputees [NA]
A Johns Hopkins University-led trial on surgical treatments for neuroma-related pain in amputees has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2025-05-22Clinical Trial Update: Noninvasive Modulation of Chronic Neuropathic Pain [Phase 1, Phase 2]
A Phase 1/2 clinical trial evaluating noninvasive modulation of chronic neuropathic pain has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2024-09-19Clinical Trial Update: Study of Efficacy and Safety of Gabapentin to Reduce the Need for Strong Opioid Use in Head and Neck Cancer Patients. [Phase 3]
Phase 3 trial evaluating gabapentin to reduce the need for strong opioid use in head and neck cancer patients has been withdrawn. The study …
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS withdrawal · 2024-06-14Clinical Trial Update: Treatment of Frostbite Sequelae With Botulinum Toxin A [Phase 2]
Phase 2 trial evaluating botulinum toxin A for frostbite sequelae has been withdrawn.
-
EMA withdrawal · 2023-03-20EMA Withdrawn: Pregabalin Zentiva k.s. (pregabalin) — Zentiva k.s.
The EMA withdrew pregabalin Zentiva k.s. from the market (Zentiva k.s.) with the therapeutic areas including anxiety disorders, neuralgia, a…
-
EMA withdrawal · 2022-04-26EMA Withdrawn: Pregabalin Mylan Pharma (pregabalin) — Mylan S.A.S.
EMA withdrawal notice for pregabalin marketed by Mylan S.A.S., affecting anxiety disorders, neuralgia, and epilepsy indications.
-
CLINICAL_TRIALS withdrawal · 2018-08-13Clinical Trial Update: Early Administration of Botox® in Neuropathic Pain Due to Thoracoscopy or Thoracotomy [Phase 3]
Phase 3 trial on early administration of Botox in neuropathic pain after thoracoscopy/thoracotomy was withdrawn.
-
CLINICAL_TRIALS withdrawal · 2018-04-12Clinical Trial Update: Effectiveness of Repetitive Transcranial Magnetic Stimulation in the Treatment of Chronic Neuropathic Pain
The clinical trial evaluating repetitive transcranial magnetic stimulation for chronic neuropathic pain has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2016-07-27Clinical Trial Update: Study to Evaluate the Efficacy and Safety of DS-1971a for the Treatment of Diabetic Peripheral Neuropathic Pain (DPNP) [Phase 2]
A Phase 2 trial evaluating DS-1971a for diabetic peripheral neuropathic pain has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2012-04-30Clinical Trial Update: Transcranial Magnetic Stimulation (TMS) Effects on Pain Perception [Phase 2, Phase 3]
A Phase 2/3 clinical trial evaluating transcranial magnetic stimulation for pain perception was withdrawn, with conditions including trigemi…